This is where developments land: a platform we review changing its price, panel, or regulatory standing, or new research in a category we publish. Each briefing summarizes what happened in a sentence or two, then spends most of its length on the part a wire story leaves out: what the development does and does not change for someone choosing between these platforms.
Every figure on these pages is copied from a source we fetched and read, linked by name. We do not rewrite evergreen review pages here; those live under their category hubs. Ordering is by date, newest first, and carries no ranking.
Remnant and Lp(a) Protein Scores Predicted Heart Disease After Adjusting for the Measured Level
Across 2,918 proteins in 35,269 UK Biobank adults, the triglyceride-rich and Lp(a) signatures shared 36 inflammatory-pathway proteins and still predicted coronary disease once the measured lipoprotein levels were accounted for (HR 1.16 and 1.09 per SD). The LDL signature did not. No protein test exists to order.
A Gut-Microbe Fatty Acid Halved Artery Plaque in Mice by Hitting the Statin Enzyme
Pentadecanoic acid from Bacteroides uniformis inhibited HMG-CoA reductase and cut aortic plaque by about half in male mice, with knockout and low-producing strains confirming the mechanism. The one human randomised trial measured cholesterol in 88 women with fatty liver, not plaque.
Walnuts Moved a Diet Score by 0.64 Points, Not a Blood Marker
In an ancillary analysis of the 2-year WAHA trial, 166 older adults eating 1 to 2 oz of walnuts daily scored a mean Dietary Inflammatory Index of -0.025 against 0.615 in 153 controls. The index is computed from reported food intake, the analysis was exploratory, and the California Walnut Commission funded it.
A Review Argues Yo-Yo Dieting Risk Splits by Where You Started
Two researchers argue in Nature Reviews Endocrinology that repeated loss and regain costs people with obesity little, while lean people lose proportionally more fat-free mass and may regain it as fat. It is a perspective review, not a trial, and the direct comparison it calls for has not been run.
Low Hemoglobin Dementia Risk Was 16 Percent Higher in One Korean Cohort
In 316,542 Korean adults followed up to 15 years, the lowest hemoglobin fifth had 16% higher all-cause dementia risk and the highest fifth 7%. Why a U-shape and reverse causation stop this being a number you can read off your own panel.
Fiber Cut Calorie Absorption by 116 kcal in a Clinical Trial
A 17-person metabolic-ward crossover sent 116 ± 56 kcal/day more energy out in feces on a high-fiber diet, cutting metabolizable intake from 95.4% to 89.5%. The new model is fitted to those same 17 people, and no test you can buy measures this.
Does Exercise Help Menopause Depression?
A UCL review of 12 randomized trials in more than 1,000 peri- and early-postmenopausal women found aerobic activity helped depressive symptoms most. Many trials were at high risk of bias and no pooled effect size was published.
GLP-1 Nail Detachment Study Finds Reports Clustered in Users
Two cross-sectional analyses of 575 GLP-1 users and 1,329 nonusers found nail detachment reported by 39% against 9%. Symptoms were self-reported, and about half of users had nail problems before treatment.
CBL-514 Visceral Fat Trial: What the Human Data Shows
An MRI subgroup of 40 people saw visceral fat fall 12.01% on CBL-514 while placebo rose 5.68%. The weight regain claim attached to the headline comes from rats.
Viome CancerDetect Pancreatic: What the Validation Shows and Leaves Unanswered
Viome PRO launched a pancreatic cancer blood test reporting 86% early-stage sensitivity. The figure comes from known-cancer versus healthy samples, with no sample size published.
Suita Study Evaluates Lp(a) Carotid Plaque Progression over a Decade
In 3,272 Japanese adults followed 11.5 years, Lp(a) at or above 50 mg/dL carried a 1.27 hazard ratio for new plaque and more than twice the odds of severe stenosis.
A Preinvasive Regulatory T Cell Lung Cancer Blood Test Remains Years from Clinical Use
A UCL Nature paper found regulatory T cells accumulate before lung cancer. The blood tests are prototypes, the drug result was in mice, and no accuracy figures were published.
Automated Breast Ultrasound vs Handheld in Dense Breasts
A 25,328-exam Breast Cancer Surveillance Consortium analysis found similar cancer detection between automated and handheld ultrasound, with fewer false alarms for automated.
Viome Solaria Bio Acquisition and the Evidence Behind the Bondia 85% Bone Density Claim
Viome acquired Solaria Bio to sell Bondia without a test. The trial behind the 85% bone density claim missed its primary endpoint across all 286 women.
GlycanAge Unilabs Middle East: What Changes When a Clinic Orders the Test
Unilabs Middle East introduced GlycanAge biological age testing across its network. Here is how the clinical route differs from direct consumer kits.
Vitamin D2 vs D3: 11 Trials Find Ergocalciferol Lowers D3
A meta-analysis of 11 randomized controlled trials found vitamin D2 supplementation lowered circulating 25-hydroxyvitamin D3 compared to controls.
A Pilot Trial Tracked Weight Regain After Stopping GLP-1
A 39-person pilot trial evaluated weight regain after stopping GLP-1 drugs with meal delivery or Noom. Weight was a secondary endpoint.
The 104-Week SWITCH Trial on Diet Drinks vs Water Weight Loss Found No Clear Winner
The SWITCH trial evaluated diet drinks vs water weight loss over 104 weeks in 493 adults. The 1.1 kg difference between groups was not statistically significant.
An FDA panel backed Galleri 7-2 but split 6-4 on whether it works
The Molecular and Clinical Genetics Devices Panel voted 10-0 on safety, 7-2 with one abstention on benefit-risk, and 6-4 on effectiveness. An advisory vote is not an approval, and the FDA decision is still pending.
A 15-person CRISPR trial cut LDL by half and kept it there for a year
One-year data on CTX310, a CRISPR-Cas9 edit of the ANGPTL3 gene, reports a 52.5 percent mean LDL reduction at the highest dose. The trial was open-label with no control group, and one of the 15 participants died 179 days after the lowest dose.
Semaglutide added close to 100 days to the lifespan of old mice
A Nature study started semaglutide in 20-month-old female mice and reported a median lifespan close to 100 days longer. A calorie-matched comparison group ate the same reduced amount of food and did worse on spatial memory and blood-sugar maintenance.
A genetic study links GLP-1 receptor activity to male pattern hair loss
NYU Langone researchers used two-sample Mendelian randomization on the GLP1R gene across 205,327 men and report a 7 percent added risk of androgenetic alopecia. Nobody in the analysis was recorded as taking the drugs.
A 124,387-person Swedish study ranked family cancer count above a relative's age at diagnosis
Karolinska Institutet followed 124,387 people with inflammatory bowel disease for a median of 11 years. Two or more first-degree relatives with colorectal cancer carried about 2.6 times the risk, against just under 50 percent higher for one relative diagnosed before 50.
Two 2026 reviews looked at testosterone and heart rhythm and reached opposite conclusions
A Journal of the Endocrine Society review argues both low and high testosterone raise atrial fibrillation risk, naming 350-550 ng/dL as the target. A second 2026 review of overlapping evidence concludes the opposite. Neither pooled any data.
Two evolocumab trials reported the same day split on what a lower LDL buys
VESALIUS-CV randomized 12,257 high-risk patients and reported 20% lower all-cause mortality over a median of 4.6 years. AMUNDSEN doubled LDL goal attainment after a heart attack and found no clinical difference at 12 months.
A 38-trial review puts numbers on GLP-1 weight loss, and warns against pooling them
An updated Annals of Internal Medicine review of 38 randomized trials and 25,816 adults without diabetes reports placebo-subtracted weight loss from -5.8% for liraglutide to -23.9% for amycretin. The authors state heterogeneity precluded quantitative synthesis.
A new GLP-1 psychiatric safety review lands on evidence thinner than the headlines
A 2026 review reports no link between GLP-1 drugs and serious psychiatric harm, matching a 2024 EMA conclusion. The pooled meta-analytic estimate spans a risk ratio of 0.077 to 4.205, and most trials excluded people with a history of mental illness.
A 9,971-person statin trial over age 70 missed its primary endpoint
STAREE randomized 9,971 adults over 70 to atorvastatin 40 mg or placebo. Major cardiovascular events fell from 8.3% to 6.0% over a median of 5.9 years. Disability-free survival, the trial's primary endpoint, did not differ.
Keto cut liver fat 67% at the same weight loss as two other diets
A 55-person randomized trial at Washington University supplied every meal for five months. Liver fat fell 67% on a ketogenic diet against 45% on Mediterranean and plant-forward diets, with weight loss matched at about 10%.
A 2,501-man trial improved cholesterol without reducing heart attacks
RADICAL PC 2 randomized men with prostate cancer to a cardiology referral or usual care. Statin use rose from 40% to 63% and cholesterol fell, and cardiovascular events did not differ over nearly six years.
A 17,024-man analysis links ultra-processed food to prostate cancer — in data that cannot show which came first
An FAU-led analysis of NHANES 2003–2023 reports 24% to 31% higher prostate cancer risk in men eating more ultra-processed food. The design is cross-sectional, and no confidence intervals were published.
A 183,450-woman cohort links HRT use to a lower rate of dementia
In the UK Biobank, postmenopausal women who used hormone replacement therapy for a year or more had a 10% lower rate of dementia. The subgroup results and the absolute numbers behind that figure.
An Alzheimer's sleep study measured brain waves consumer trackers do not report
A 60-person Neurology study linked NREM sleep spindles and slow oscillations to CSF orexin and to 36-month cognitive outcomes in diagnosed Alzheimer's disease. Why a deep sleep score is not the same measurement.
A Stanford analysis ties LDL increases on low-carb diets to a genetic score
A secondary analysis of the DIETFITS trial found that people with a higher polygenic tendency toward high LDL saw larger increases on a low-carb diet. No effect sizes were released, and the abstract is not peer reviewed.
A federal guideline reviewed the body fat measurements and endorsed none of them
The 2025 VA/DoD obesity guideline found insufficient evidence to recommend any particular measure of adiposity for managing clinical outcomes. What that reframes about DEXA scans and visceral fat ratings.
Galleri gets a payer route through a Michigan health plan
Priority Health is enabling Michigan self-insured employer groups to add GRAIL's Galleri test to existing cancer screening coverage. One state, one plan, and the first payer route into a self-pay tier.
An Alzheimer's blood test just got cleared — and the clearance says it is not for screening
The FDA cleared C2N Diagnostics' PrecivityAD2 for adults 40+ who already have signs of cognitive impairment. The indication rules out screening, and the intermediate result band is the number worth reading.
A research team compressed the gut microbiome into one number — here is what it tracked
A Microbial Health Index built from 97 health-associated and 31 disease-associated bacterial variants correlated with diet, fitness and lipids in 893 adults. No accuracy figures were reported.
Function Health takes $450M in growth financing — what it changes for buyers
Function closed $450 million from General Catalyst's Customer Value Fund, described as non-dilutive. Why customer-acquisition capital shows up in the price list rather than the panel.
The cheapest high-evidence screening test is the one almost nobody discusses
University of Cincinnati researchers found just 15% of eligible US adults had discussed lung cancer screening with a doctor, against 70–80% for colonoscopy and mammography.
A 376,511-person cohort quantifies what colorectal screening buys you
In the Stockholm-Gotland program, participating in fecal occult blood screening was associated with a 43% lower rate of colorectal cancer death. What that number is, and what it means for self-pay screening.
A small trial tested fasting windows in type 1 diabetes — carefully
A 32-person randomized trial at UIC found time-restricted eating lowered HbA1c relative to calorie counting, without raising hypoglycemia or ketoacidosis risk. What a pilot of this size does not settle.
WHOOP drops the membership requirement for lab testing — and adds Galleri
WHOOP and Quest made Advanced Labs available without a WHOOP membership and added GRAIL's Galleri multi-cancer test. Why the membership change matters more than the headline.
A tape measure outpredicted epigenetic clocks in a Finnish cohort
In 1,108 middle-aged Finns followed 7–9 years, BMI, waist-to-hip ratio, smoking and alcohol predicted new chronic disease better than the epigenetic clocks tested.
Galleri heads to an FDA advisory panel
The FDA set a September 23, 2026 advisory-committee review of the Galleri multi-cancer blood test. What the meeting does and does not change for a buyer.
InsideTracker adds a source-agnostic blood-data connector
InsideTracker will read blood results from outside labs, PDFs, Apple Health and EMRs across nearly 120 markers. Why it matters for buyers who already have bloodwork.
A research blood test targets bile acids, an overlooked liver marker
University of Toledo researchers report a fast whole-blood test for elevated bile acids, validated in 23 patients. Early-stage, research-only, and what it says about panel breadth.
How these briefings are built
Detection is only a signal. A headline from an aggregator is never enough to publish from, because those links do not resolve to article text. Before a briefing ships, the underlying event is re-grounded in a fetchable primary source: a company's own newsroom, the trade outlet that broke it, an FDA or court record, or the journal paper itself. If no primary source states the claim, the story is dropped rather than written. Prices, doses, lab ranges and study numbers come from that source or an official page, never from a headline.
The Two Kinds of Story That Land Here
Briefings arrive in two streams. Platform news covers what the companies on our review roster did: a funding round, a panel or price change, an FDA action, a lawsuit, a clinical validation of their own test. Those matter because they change the thing a reader is choosing between, and they rarely reach the review pages fast enough on their own.
Science covers new research in a category we already publish. A trial readout, a cohort result, a guideline change, or a safety signal on something readers use. A finding qualifies when it could change what someone does or believes, and a mechanism paper with no human read does not qualify however interesting it is.
Most candidates never become a page. A story gets dropped when no primary source can be found, when the development is already documented on an existing guide, when the real subject falls outside what this site covers, or when a headline turns out to be recycled coverage of something months old. Dropping is the normal outcome, and the volume of it is what keeps the pages that do ship worth reading.
A briefing never rewrites an evergreen page. When a development makes an existing review stale, the correction is handled on that review, and the briefing stays a dated record of what changed and when. That separation keeps a decaying news item from diluting a guide people arrive at through an evergreen question years later.
Related
- Longevity platforms, compared: all on one rubric
- Biomarker guides: what the panels actually measure
- How we review